Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov;9(11):907-921.
doi: 10.1016/S2215-0366(22)00317-0.

Maintenance ketamine treatment for depression: a systematic review of efficacy, safety, and tolerability

Affiliations

Maintenance ketamine treatment for depression: a systematic review of efficacy, safety, and tolerability

Sanne Y Smith-Apeldoorn et al. Lancet Psychiatry. 2022 Nov.

Abstract

Ketamine has rapid yet often transient antidepressant effects in patients with treatment-resistant depression. Different strategies have been proposed to prolong these effects. Maintenance ketamine treatment appears promising, but little is known about its efficacy, safety, and tolerability in depression. We searched Pubmed, Embase, and the Cochrane Library and identified three randomised controlled trials, eight open-label trials, and 30 case series and reports on maintenance ketamine treatment. We found intravenous, intranasal, oral, and possibly intramuscular and subcutaneous maintenance ketamine treatment to be effective in sustaining antidepressant effect in treatment-resistant depression. Tachyphylaxis, cognitive impairment, addiction, and serious renal and urinary problems seem uncommon. Despite the methodological limitations, we conclude that from a clinical view, maintenance ketamine treatment seems to be of therapeutic potential. We recommend both controlled and naturalistic studies with long-term follow-up and sufficient power to determine the position of maintenance ketamine treatment within routine clinical practice.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests JKEV received a speaker's fee from Janssen Pharmaceuticals, outside the submitted work. RAS received research funding for two randomised clinical trials with generic oral esketamine from the Netherlands Organisation for Health Research and Development and the National Health Care Institute, a speaker's fee and investigator initiated research grant from Janssen Pharmaceuticals, and consultancy fees from GH Research, Beckley PsyTech, and QPS, outside the submitted work. The other authors declared no competing interests.

Similar articles

Cited by

Publication types

MeSH terms

LinkOut - more resources